Tg Therapeutics (TGTX) Retained Earnings (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Retained Earnings of $1.8 billion for Q1 2026, up 223.03% year-over-year from $571.3 million in Q1 2025, and up 0.84% quarter-over-quarter from $1.8 billion in Q4 2025.
Tg Therapeutics (TGTX) Retained Earnings (2010 - 2026) Analysis & Trends
Tg Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at $1.8 billion for Q1 2026.
- In Q1 2026, Retained Earnings rose 223.03% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 223.03% YoY), while the FY2025 annual figure was $1.8 billion, up 219.68% from the prior year.
- Retained Earnings for Q1 2026 stood at $1.8 billion, up from $1.8 billion in the prior quarter.
- The five-year high for Retained Earnings was $1.8 billion in Q1 2026, with the low at -$1.6 billion in Q2 2023.
- The 5-year median for Retained Earnings is -$1.5 billion (2022), against an average of -$733.7 million.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings tumbled 195.29% in 2022, then surged 223.03% in 2026.
- Tg Therapeutics' Retained Earnings stood at -$1.5 billion in 2022, then soared by 214.21% to $1.7 billion in 2023, then sank by 189.26% to -$1.5 billion in 2024, then soared by 219.68% to $1.8 billion in 2025, then rose by 0.84% to $1.8 billion in 2026.
- Business Quant data shows TGTX's Retained Earnings at $1.8 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 1.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.86 Bn |
| Mar 31, 2026 | 1.85 Bn |
| Dec 31, 2025 | 1.83 Bn |
| Sep 30, 2025 | 1.81 Bn |
| Jun 30, 2025 | -1.50 Bn |
| Mar 31, 2025 | -1.50 Bn |
| Dec 31, 2024 | -1.53 Bn |
| Sep 30, 2024 | -1.60 Bn |
| Jun 30, 2024 | -1.56 Bn |
| Mar 31, 2024 | -1.50 Bn |
| Dec 31, 2023 | 1.71 Bn |
| Sep 30, 2023 | -1.50 Bn |
| Jun 30, 2023 | -1.61 Bn |
| Mar 31, 2023 | -1.60 Bn |
| Dec 31, 2022 | -1.50 Bn |
| Sep 30, 2022 | -1.47 Bn |
| Jun 30, 2022 | -1.40 Bn |
| Mar 31, 2022 | -1.40 Bn |
| Dec 31, 2021 | -1.33 Bn |
| Sep 30, 2021 | 1.55 Bn |